about
Data mining The Cancer Genome Atlas in the era of precision cancer medicineMulticenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in SwitzerlandThe epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors.Antagonistic cross-regulation between Sox9 and Sox10 controls an anti-tumorigenic program in melanoma.Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanomaIn vivo profiling reveals immunomodulatory effects of sorafenib and dacarbazine on melanoma.Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?Loss of Ezh2 promotes a midbrain-to-forebrain identity switch by direct gene derepression and Wnt-dependent regulationCo-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance.Coexpression of SOX10/CD271 (p75(NTR)) and β-Galactosidase in Large to Giant Congenital Melanocytic Nevi of Pediatric Patients.sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistancePARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas.Proteomics approaches to understanding mitogen-activated protein kinase inhibitor resistance in melanoma.Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL.Ingenol Mebutate Signals via PKC/MEK/ERK in Keratinocytes and Induces Interleukin Decoy Receptors IL1R2 and IL13RA2.Metastatic melanoma moves on: translational science in the era of personalized medicine.Transcriptional repression of IFNβ1 by ATF2 confers melanoma resistance to therapy.Diffuse Cutaneous Melanosis Associated with Malignant Melanoma.Basal cell carcinomas in a tertiary referral centre: a systematic analysis.Hedgehog pathway inhibitors promote adaptive immune responses in basal cell carcinoma.Systematic classification of melanoma cells by phenotype-specific gene expression mapping.Metastatic melanoma cell lines do not secrete IL-1β but promote IL-1β production from macrophages.Small molecule promotes β-catenin citrullination and inhibits Wnt signaling in cancer.low neurotrophin receptor CD271 regulates phenotype switching in melanoma.Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect phenotype switching?Publisher Correction: The low affinity neurotrophin receptor CD271 regulates phenotype switching in melanoma.Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of Klotho.A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma.Germinal centers determine the prognostic relevance of tertiary lymphoid structures and are impaired by corticosteroids in lung squamous cell carcinoma.Wnt-signaling enhances neural crest migration of melanoma cells and induces an invasive phenotype.Medical bioinformatics in melanoma.Sox2 is dispensable for primary melanoma and metastasis formation.An exploratory study investigating the metabolic activity and local cytokine profile in patients with melanoma treated with pazopanib and paclitaxel.Osmoregulatory function of large vacuoles found in notochordal cells of the intervertebral disc running title: an osmoregulatory vacuole.CARD14 gain-of-function mutation alone is sufficient to drive IL-23/IL-17-mediated psoriasiform skin inflammation in vivo.In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms.Corrigendum: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance.Proteomics-based insights into mitogen-activated protein kinase inhibitor resistance of cerebral melanoma metastases.Melanoma Immunotherapy: Next-Generation Biomarkers.Increased tumour cell PD-L1-expression, macrophage and dendritic cell infiltration characterise the tumour microenvironment of ulcerated primary melanomas
P50
Q26786399-70669223-7677-4FB8-ABB0-22C93DD79145Q30491702-0E1F0CEB-5466-4831-959D-953CDCFB43D9Q34459061-C226E507-977E-4BA8-B911-864DE5891372Q35023613-42309FC9-BCB1-43D0-AB9F-F713338F6599Q35229597-9AD7FF69-51A9-4969-8B9A-536B2A465F9BQ35506764-A654604F-90D2-408A-8E31-7C5D87F88433Q35794989-D829ECF4-B060-4F27-BD2B-1E5EFE01D4B9Q35856427-840F76F9-6E15-4BA0-8139-FD5BD50CA754Q36176934-753212A4-37D7-458B-815F-92548E72C99CQ36636018-BF95564D-7081-4782-A0CA-038B5B5AE9DDQ36803498-00DBFB81-C529-4DE8-BF22-7F47B67F68F2Q37688982-B769A7DF-2B4F-4B1C-81B4-E4EB584C71FAQ38689427-2810A968-8C13-4AB1-A034-A5A88E77FF12Q38812165-1B8C6E3B-3CBF-4E1C-A142-E6C6184B20FAQ38859614-CB54575A-8B4C-4071-8193-E913D6B1E981Q38891959-C5430046-51DA-4253-BB20-087187079E12Q38904811-7D690D57-4F13-4468-9432-211D78999713Q41518866-F59EC0D6-2A0D-485D-8BE5-E420C9AEE0DFQ42461410-41F244AB-5B0A-4BF0-9EAA-4FD7E9E86C1CQ42471540-B151FF67-2B46-4D10-B9F0-27CA1B6004E0Q42818733-83DD9EF9-D441-4BA2-838F-7832F44337A9Q42825646-D2864DBB-822B-428D-91A1-CB10978C2941Q45071326-D70B6456-21CD-440D-B69C-CD5B215D64C6Q47103221-33559085-D075-4D3C-980F-46ACAE4EB819Q48351638-FF103B21-D5EF-416B-A312-3C82A4956DA7Q48512698-41FEAE87-C5EE-43A3-AD4D-3BCBBAE6B244Q48823012-C4781052-13A3-4813-8F79-35A697E2059EQ49181142-4A92EFCE-C4C5-465F-B7D9-2BC8BAC0CA15Q49568363-1D102751-4A4E-479C-A880-4C53FDE122FAQ49900550-E89B10CC-9EC7-4E40-AE58-6766548D51BFQ49950790-192636C7-B284-4F24-9F40-55BDF67C9BFAQ51075741-83E298E2-4A5A-4E76-9954-861F6B9EC472Q51746622-D3889CCD-3641-4FD6-B2C3-FF583840BFDEQ51789515-05986AA1-3D89-4AF0-A659-2F3583237A2AQ52310988-96362C65-77EF-4B87-A3B7-24FFD3A0CE0EQ52729471-3F96C125-6C24-4F81-ACFF-F673FC24B1B4Q53778479-1DD92150-6691-454C-A700-65B2F41BF6A2Q54982136-6E942C35-7BA8-4F5A-93A6-B8FF5D8BB382Q55156734-C425A38A-CE58-419B-97C2-EB5A267A0017Q57787313-ACE668E1-DB5A-44D5-83AC-0CE888FB16CF
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Phil F Cheng
@ast
Phil F Cheng
@en
Phil F Cheng
@es
Phil F Cheng
@nl
Phil F Cheng
@sl
type
label
Phil F Cheng
@ast
Phil F Cheng
@en
Phil F Cheng
@es
Phil F Cheng
@nl
Phil F Cheng
@sl
prefLabel
Phil F Cheng
@ast
Phil F Cheng
@en
Phil F Cheng
@es
Phil F Cheng
@nl
Phil F Cheng
@sl
P106
P21
P31
P496
0000-0003-2940-006X
P569
2000-01-01T00:00:00Z